A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors.

Saved in:
Bibliographic Details
Title: A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors.
Authors: Liang R; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Tomita D; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Sasaki Y; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Ginn J; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Michino M; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Huggins DJ; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States.; Department of Physiology and Biophysics, Weill Cornell Medical College, New York, New York 10021, United States., Baxt L; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Kargman S; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Shahid M; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.; Epigenetics Program, Perelman School of Medicine, Philadelphia, Pennsylvania 19104, United States.; Abramson Cancer Center, Perelman School of Medicine, Philadelphia, Pennsylvania 19104, United States., Aso K; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Duggan M; LifeSci Consulting, LLC., 18243 SE Ridgeview Drive, Tequesta, Florida 33469, United States., Stamford AW; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., DeStanchina E; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States., Liverton N; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Meinke PT; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States.; Department of Pharmacology, Weill Cornell Medical College, New York, New York 10021, United States., Foley MA; Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, New York, New York 10021, United States., Phillips RE; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.; Epigenetics Program, Perelman School of Medicine, Philadelphia, Pennsylvania 19104, United States.; Abramson Cancer Center, Perelman School of Medicine, Philadelphia, Pennsylvania 19104, United States.
Source: ACS medicinal chemistry letters [ACS Med Chem Lett] 2022 Feb 10; Vol. 13 (3), pp. 377-387. Date of Electronic Publication: 2022 Feb 10 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101521073 Publication Model: eCollection Cited Medium: Print ISSN: 1948-5875 (Print) Linking ISSN: 19485875 NLM ISO Abbreviation: ACS Med Chem Lett Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1948-5875
DOI:10.1021/acsmedchemlett.1c00448